Inve US ▾
POPODD

Insulet (PODD) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Insulet Q2 FY26 — Strong Revenue Growth, Type 2 Retention Challenges Lead to Revised Outlook

Insulet delivered strong Q2 FY26 results with robust revenue growth and significant margin expansion, driven by demand for Omnipod across markets. However, the company revised its full-year revenue outlook due to unexpected challenges in Type 2 customer utilization and retention, particularly in the first 90 days of therapy. Management is implementing decisive actions to address these execution challenges and remains confident in the long-term opportunity within the underpenetrated Type 2 market.

Highlights

5

  • Total company revenue grew 23% year-over-year on a constant currency basis, exceeding expectations.

  • Adjusted operating margin increased 140 basis points year-over-year to 19.3%.

  • Adjusted EPS increased approximately 42% to $1.36, nearly twice the rate of revenue growth.

  • Global new customer starts increased sequentially and year-over-year, contributing to 23% growth in the global customer base.

  • Added coverage for an additional 6.5 million lives and reduced prior authorization barriers for approximately 10 million lives.

Concerns

4

  • Lower rates of utilization and retention among Type 2 customers were more pronounced than anticipated, leading to a revised full-year revenue outlook.

  • Full-year 2026 total company revenue growth outlook revised down to 20%-22% (constant currency).

  • U.S. Omnipod growth outlook revised down to 17%-19% for the full year.

  • Slightly lower positive pricing anticipated due to timing and mix of commercial investments, accounting for 1/3 of the guidance update.

Guidance & targets

CategoryTargetConfidence
Total Company Revenue Growth
20%-22%
high materiality
High
U.S. Omnipod Revenue Growth
17%-19%
high materiality
High
International Omnipod Revenue Growth
30%-32%
high materiality
High
Total Omnipod Revenue Growth
21%-23%
high materiality
High
FX Contribution to Total Company/Omnipod Revenue
100 bps
medium materiality
High
FX Contribution to International Omnipod Revenue
300 bps
medium materiality
High
Adjusted Operating Margin Expansion
approximately 100 basis points
high materiality
High
Net Interest Expense
$40 million
medium materiality
High
Non-GAAP Tax Rate
20%-21%
medium materiality
High
Shares Outstanding
approximately 70 million
medium materiality
High
Adjusted EPS Growth
at least 30%
high materiality
High
Free Cash Flow
down modestly from 2025 levels
medium materiality
Medium
Omnipod Revenue Growth
18%-20%
high materiality
High
Total Company Revenue Growth
17.5%-19.5%
high materiality
High
FX Headwind to Total Company/Omnipod Revenue
approximately 50 basis points
medium materiality
High
U.S. Omnipod Revenue Growth
14%-16%
high materiality
High
International Omnipod Revenue Growth
28%-30%
high materiality
High
FX Headwind to International Omnipod Revenue
approximately 200 basis points
medium materiality
High
Total Company Constant Currency Revenue Growth Exit Rate
mid-teens
high materiality
High
Total Company Constant Currency Revenue Growth
consistent with or better than mid-teens exit rate
high materiality
Medium
Adjusted Operating Margin Expansion
approximately 100 basis points annually
high materiality
High
Adjusted EPS CAGR
more than 25%
high materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
U.S. Omnipod
Driven by continued demand across both Type 1 and Type 2 customers.
—20%——
International Omnipod
Driven primarily by volume and continued favorable price/mix realization.
Reported growth: >35%New users in Australia: #1 insulin pumpNew market entry: Spain
—33%——

Product announcements

ProductTypeDetails
Omnipod Discoverlaunch
Omnipod 5 algorithm enhancementsupdate

Risks & headwinds

Lower utilization and retention among Type 2 customers Q2 FY26, expected to continue through H2 FY26

Accounts for approximately 2/3 of the change to prior full-year guidance.

Mitigation:Expanding customer care team, changing sales force compensation to prioritize retention, refining sample deployment, rolling out Omnipod Discover, accelerating customer data platform development.

Slower new customer starts than anticipated Q1 FY26

Accounts for approximately 1/3 of the change to prior full-year guidance (combined with pricing).

Mitigation:Overall commercial efforts, including sales force expansion and DTC activations.

Slightly lower positive pricing Full Year 2026

Accounts for approximately 1/3 of the change to prior full-year guidance (combined with NCS).

Mitigation:Timing and mix of commercial investments that support customer access and long-term growth, rather than competitive pricing dynamics.

What to watch in Q3 FY26

Type 2 customer retention and utilization rates

Next quarter (Q3 FY26 results)
Current Lower than anticipated, particularly in the first 90 days.
Target Improved stabilization of retention rates, especially post-90 days.

Why it matters

This is the primary driver of the revised full-year guidance and a key factor for long-term Type 2 market penetration.

We're updating our full year revenue outlook to incorporate the utilization and retention trends we are seeing within our Type 2 customer base and to reflect the time required for the actions we are taking to translate into improved customer success.

Find out whether PODD delivers this. Inve re-checks your case every morning.

Q&A highlights

What changed regarding Type 2 trends since ADA, when did attrition start, and what are the assumptions for 2027 regarding competition and pricing given the U.S. exit rate?

Ashley acknowledged accountability for not identifying Type 2 trends sooner, stating Q2 saw emerging retention/utilization issues. She emphasized it's an execution challenge, not structural (not pricing, competition, or GLP-1 related). Flavia added that the 2027 outlook contemplates competitive entrants and stable pricing, and does not assume improvement from current actions.

“I just need to acknowledge upfront that we should have understood some of these Type 2 trends sooner and done a better job of adapting our commercial and customer service model to the needs of this really important customer base, which is the Type 2. And as CEO, I take accountability for that.”

asked by Robert Marcus · answered by Ashley McEvoy

2 min read 6 chapters

Detailed narrative

Q2 Performance Highlights

Insulet reported strong Q2 FY26 results, with total company revenue growing 23% constant currency to $802 million, exceeding expectations. This was driven by robust demand for Omnipod in both U.S. and international markets, alongside favorable price/mix. Profitability also expanded significantly, with adjusted operating margin up 140 basis points to 19.3% and adjusted EPS increasing 42% to $1.36, demonstrating strong earnings leverage.

Type 2 Diabetes Market Dynamics and Challenges

While demand for Omnipod among Type 2 customers remains strong, representing over 40% of new customer starts, the company observed lower utilization and retention rates, particularly within the first 90 days of therapy. Management attributes this to an execution challenge in adapting its commercial model and customer support to the unique needs of Type 2 Podders, who often have different emotional burdens, higher comorbidities, and are managed by PCPs. This led to a revised full-year revenue outlook.

Actions to Improve Type 2 Retention and Utilization

In response to the Type 2 challenges, Insulet is implementing decisive actions. These include expanding its customer care team, changing sales force compensation to prioritize longer-term retention over new starts, refining sample deployment to target high-benefit patients, and rolling out new technology platforms like Omnipod Discover. Omnipod Discover, a cloud-based platform for providers and patients, has shown promising early results in improving clinical outcomes and retention among its 12,000 users and 1,600 HCPs.

Innovation Pipeline and Future Products

Insulet is advancing a robust innovation roadmap, including annual algorithm enhancements for Omnipod 5, the upcoming Omnipod 6 (with pivotal STRIVE data showing improved time in range), and a breakthrough fully closed-loop system for Type 2 diabetes. The fully closed-loop system, designed for simplicity with no bolusing or manual titration, is expected to have a 510(k) submission in 2027 and aims to broaden AID access, especially for the 70% of Type 2 patients managed in primary care.

Commercial Capabilities and Market Access

The company continues to invest in its market-leading brand, direct-to-consumer (DTC) activations, professional education, and sales force expansion. Efforts to expand access and affordability resulted in adding coverage for 6.5 million lives and simplifying prior authorization requirements for approximately 10 million lives during the quarter, reflecting a strategy focused on broad access rather than exclusionary positions.

Long-Term Outlook and Strategic Pillars

Despite the near-term adjustment to revenue guidance, Insulet remains highly confident in the long-term opportunity, citing AID's significant underpenetration, its robust innovation pipeline, expanding commercial capabilities, unmatched manufacturing network, and recurring revenue business model. The company expects to provide an updated long-range outlook on its Q4 call, but anticipates delivering top-tier revenue growth, meaningful margin expansion, and strong earnings growth.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.